IMU-838 22.5 mg tablet clinical trials

Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)

This study, called REVIVE, is looking at new ways to treat Post-COVID Syndrome (long COVID). It will test different doses of a medicine called IMU-838 to see if it helps improve physical abilities in people still experiencing symptoms after having COVID.